<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165476</url>
  </required_header>
  <id_info>
    <org_study_id>TDE-PH-121</org_study_id>
    <nct_id>NCT01165476</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities</brief_title>
  <official_title>An Evaluation of the Comparative Bioavailability of a Single Oral Dose of 1mg UT-15C (Treprostinil Diethanolamine) SR Tablets Manufactured by Two Independent Facilities Administered to Healthy Volunteers in the Fed State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the bioavailability of a single 1mg dose of
      treprostinil diethanolamine sustained release (SR) tablets manufactured by two independent
      facilities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treprostinil pharmacokinetics</measure>
    <time_frame>36 hours</time_frame>
    <description>Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of 1mg treprostinil diethanolamine collecting pre and post-dose levels to 36 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical lab values</measure>
    <time_frame>Days 0, 7 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event monitoring</measure>
    <time_frame>From signing of ICF to end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>manufacturer #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treprostinil diethanolamine from manufacturer #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>manufacturer #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treprostinil diethanolamine from manufacturer #2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treprostinil diethanolamine</intervention_name>
    <description>sustained release tablets. One 1mg tablet per period. Two total doses.</description>
    <arm_group_label>manufacturer #1</arm_group_label>
    <arm_group_label>manufacturer #2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is healthy and between the ages of 18 and 55 years, inclusive, at Screening

          -  Female subjects must weigh between 45 and 100 kg, inclusive, with a BMI between
             19.0-29.9 kg/m2, inclusive at Screening. Male subjects must weigh between 50 and 120
             kg, inclusive, with a BMI between 19.0-32.0 kg/m2, inclusive at Screening

          -  Subject has a medical history, physical examination, vital signs, ECG and clinical
             laboratory results within normal limits or considered not clinically significant by
             the Investigator at Screening

        Exclusion Criteria:

          -  Subject has any clinically relevant abnormality identified during the screening
             physical examination, 12-lead ECG, or laboratory examinations.

          -  Subject has a history of anaphylaxis, a documented hypersensitivity reaction, or a
             clinically significant idiosyncratic reaction to any drug

          -  Subject has a clinically significant history of neurological,
             cardiovascular,respiratory, endocrine, hematological, hepatic, renal,
             gastrointestinal,genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a
             psychiatric disorder, or any other chronic disease, whether controlled by medication
             or not.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aziz L Laurent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2010</study_first_posted>
  <last_update_submitted>April 18, 2011</last_update_submitted>
  <last_update_submitted_qc>April 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Andrew Nelsen, PharmD</name_title>
    <organization>United Therapeutics</organization>
  </responsible_party>
  <keyword>treprostinil</keyword>
  <keyword>bioavailability</keyword>
  <keyword>bioequivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

